Men with hypogonadism treated long-term with testosterone therapy experience improvements in sexual and urinary function compared with men who are not treated, according to findings published in The Journal of Urology.

Abdulmaged M. Traish, PhD, of the department of biochemistry and department of urology at Boston University School of Medicine, and colleagues evaluated data on men with total testosterone levels of 12.1 nmol/L or less and symptoms of hypogonadism assigned to parenteral testosterone undecanoate 1,000 mg for 12 weeks (n = 360; mean age, 57.4 years) or no testosterone (n = 296; mean age, 64.8 years) for up to 10 years to determine the effect of long-term testosterone therapy on urinary and sexual functions and quality of life. Follow-up was a mean of 6.5 years.

Total testosterone levels were restored to the physiological range (500 ng/dL) in the treated group during the first year and the levels remained stable through follow-up; however, mean testosterone levels remained less than 300 ng/dL in the untreated group.

The untreated group experienced increases in the international prostate symptom score during follow-up compared with decreases in the treated group. At baseline, 50% of the treated group reported mild symptoms and 50% reported moderate symptoms, and 91.5% of the untreated group reported mild symptoms and 8.5% reported moderate symptoms. At the last visit, all the treated group had mild symptoms, and 61% of the untreated group reported mild symptoms and 39% reported moderate symptoms.

Post-voiding bladder volume and score on the Aging Males’ Symptoms scale decreased in the treated group but increased in the untreated group.

Among the treated group, 17.1% had no erectile dysfunction, 30.5% had mild erectile dysfunction, 20.7% mild to moderate, 25.6% moderate and 6.1% severe. At the last visit, the proportion of treated participants without erectile dysfunction increased to 74.4%, 17.1% had mild, 7.3% had mild to moderate and 1.2% had moderate. Among the untreated group, 1.2% had no erectile dysfunction, 31.7% had mild, 52.4% had mild to moderate and 14.6% had moderate. The severity of erectile dysfunction increased in the untreated group through follow-up to 51.2% having moderate and 48.8% having severe.

Prostate volume remained stable in the untreated group but increased from 31.4 mL to 33.2 mL in the treated group.

Article Source: https://www.healio.com/endocrinology/hormone-therapy/news/in-the-journals/%7B0c2f828d-0812-42fa-8f66-181eb9a8ee0f%7D/testosterone-therapy-improves-sexual-urinary-function-in-men

“The Greatest Health of Your Life”℠

Boston Testosterone Partners
National Testosterone Restoration for Men
Wellness & Preventative Medicine

http://www.BostonTestosterone.com

http://www.BTPWellness.com

http://www.facebook.com/corenewengland
855-617-MEDS (6337)

HAIR loss – or alopecia – affects half of men over the age of 30 in the UK, but using certain medications to counteract it could cause erectile dysfunction – which is the inability of a man to get and maintain an erection.

By the time they reach their fifties, over 50 per cent of men will experience some degree of baldness, according to the NHS.

The most common type of hair loss is male-pattern baldness, where sufferers often experience a receding hairline followed by thinning of hair on the crown and temples.

However, there are now a number of treatment options, and the Alopecia Treatment Market Size is set to see sustained growth between now and 2022.

These include hair transplants and medications, but experts are warning of the risks involved.

Doctors at the International Andrology London have warned that men undergoing a hair transplant could suffer erectile dysfunction as a result.

They are raising awareness of a condition called post-Finasteride Syndrome which is caused by a drug called 5-alpha reductase type II enzyme inhibitor or Finasteride.

The medication works by halting hair loss in men with thinning hair.

It also assists hair transplant treatment by stopping the body from rejecting new hair.

However, it can cause some worrying side-effects.

These include neurological and physical symptoms such as muscle atrophy, chronic fatigue and depression.

Such is their prevalence that the Post-Finasteride Syndrome Foundation has been created to boost awareness.

Dr Amr Raheem at International Andrology said: “Erectile dysfunction, loss of libido, reduction of semen creation and curvature of the penis (known as Peyronie’s) are all part of this disturbing reaction.

“Hair transplant clinics are aware of the issue and have an obligation to explain the risks to patients while the drug itself is becoming more clearly labelled.

“However, understand that investment into finding alternatives to this drug, which can provide results without compromising patients’ health, are ongoing.

“At International Andrology London, we encourage men who are developing a serious hair condition such as alopecia and know that they will need hair replacement to make a pre-emptive move, seeking out treatment for erectile dysfunction, such as shockwave therapy, before they experience the problem.

“This builds up muscle resistance and manages the condition through the hair treatment.

“An alternative option is to take Minoxidil spray which improves the circulation to the scalp and has been proven to help without the same side effects.”

Written By LAUREN CLARK

Article Source: http://www.express.co.uk/life-style/health/841366/hair-loss-erectile-dysfunction-transplant-treatment-medication-finasteride-alopecia-bald

“The Greatest Health of Your Life”℠

Boston Testosterone Partners
National Testosterone Restoration for Men
Wellness & Preventative Medicine

http://www.BostonTestosterone.com

http://www.BTPWellness.com

http://www.facebook.com/corenewengland
855-617-MEDS (6337)

People with high cholesterol live the longest.

This statement seems so incredible that it takes a long time to clear one´s brainwashed mind to fully understand its importance.

Yet the fact that people with high cholesterol live the longest emerges clearly from many scientific papers.

Consider the finding of Dr. Harlan Krumholz of the Department of Cardiovascular Medicine at Yale University, who reported in 1994 that old people with low cholesterol died twice as often from a heart attack as did old people with a high cholesterol.

Supporters of the cholesterol campaign consistently ignore his observation, or consider it as a rare exception, produced by chance among a huge number of studies finding the opposite.

But it is not an exception; there are now a large number of findings that contradict the lipid hypothesis.

To be more specific, most studies of old people have shown that high cholesterol is not a risk factor for coronary heart disease.

This was the result of my search in the Medline database for studies addressing that question.

Eleven studies of old people came up with that result, and a further seven studies found that high cholesterol did not predict all-cause mortality either.

Now consider that more than 90 % of all cardiovascular disease is seen in people above age 60 and that almost all studies have found that high cholesterol is not a risk factor for women.

This means that high cholesterol is only a risk factor for less than 5 % of those who die from a heart attack.

But there is more comfort for those who have high cholesterol; six of the studies found that total mortality was inversely associated with either total or LDL-cholesterol, or both.

This means that it is actually much better to have high than to have low cholesterol if you want to live to be very old.

High Cholesterol Protects Against Infection

Many studies have found that low cholesterol is in certain respects worse than high cholesterol.

For instance, in 19 large studies of more than 68,000 deaths, reviewed by Professor David R. Jacobs and his co-workers from the Division of Epidemiology at the University of Minnesota, low cholesterol predicted an increased risk of dying from gastrointestinal and respiratory diseases.

Most gastrointestinal and respiratory diseases have an infectious origin.

Therefore, a relevant question is whether it is the infection that lowers cholesterol or the low cholesterol that predisposes to infection?

To answer this question Professor Jacobs and his group, together with Dr. Carlos Iribarren, followed more than 100,000 healthy individuals in the San Francisco area for fifteen years.

At the end of the study those who had low cholesterol at the start of the study had more often been admitted to the hospital because of an infectious disease.

This finding cannot be explained away with the argument that the infection had caused cholesterol to go down, because how could low cholesterol, recorded when these people were without any evidence of infection, be caused by a disease they had not yet encountered?

Isn´t it more likely that low cholesterol in some way made them more vulnerable to infection, or that high cholesterol protected those who did not become infected? Much evidence exists to support that interpretation.

Written By: Uffe Ravnskov, MD, PhD

Article Source: https://www.functionalmedicineuniversity.com/public/924.cfm

“The Greatest Health of Your Life”℠

Boston Testosterone Partners
National Testosterone Restoration for Men
Wellness & Preventative Medicine

http://www.BostonTestosterone.com

http://www.BTPWellness.com

http://www.facebook.com/corenewengland
855-617-MEDS (6337)